Teva Stock Reaches New High Following Approval for Breakthrough Schizophrenia Treatment

2026-10-10 companies

Tel Aviv, Saturday, 10 October 2026.
Teva Pharmaceutical shares surged to a 52-week high of $42.02 following FDA approval of Weltruza, the first once-monthly under-the-skin schizophrenia treatment requiring no post-injection monitoring.

Market Reaction to FDA Approval

Following the announcement of regulatory clearance, Teva Pharmaceutical Industries Limited (NYSE: TEVA) experienced a significant surge in trading activity on the New York Stock Exchange. On October 9, 2026, the stock closed at $41.10 per share, reflecting a daily increase of 4.713 from the previous close of $39.25 [5]. Intraday trading reached a peak of $42.02, marking a new 52-week high for the company [1][5]. This performance extends a broader upward trend, with the stock demonstrating a 1-month increase of 11.08% leading into October 2026 [1]. Institutional investors have responded to the news with heightened activity, as trading volume reached 14.82 million shares on October 10, 2026, compared to an average daily volume of 6.15 million [3].

Weltruza Approval and Strategic Impact

The catalyst for this market movement was the U.S. Food and Drug Administration approval of WELTRUZA, a once-monthly injectable treatment for schizophrenia, announced on October 8, 2026 [4][7]. This medication, formerly known as olanzapine, is distinguished as the first and only under-the-skin shot to treat schizophrenia once a month without requiring post-injection monitoring [4][7]. Teva plans to make the treatment available in the United States in the coming weeks, positioning it to capture market share in the neurology sector [7]. The approval eliminates the need for loading doses or oral supplementation at treatment initiation, addressing key logistical barriers in schizophrenia management [7]. This development follows a strategic pivot toward innovative specialty therapeutics, complementing existing portfolios in immunology and biosimilars [2].

Financial Fundamentals and Valuation

Financial metrics indicate a complex valuation landscape as the company navigates this growth phase. As of the most recent quarter, Teva reported a Total Debt/Equity ratio of 217.79% and a Trailing Twelve Month (TTM) revenue of $17.32 billion [2]. The company maintains a cash position of $3.66 billion, with levered free cash flow recorded at $2.22 billion over the trailing twelve months [2]. Projections for 2026 indicate a Price-to-Earnings (P/E) ratio of 55.1x and net sales of $16.66 billion [1]. While the stock has risen 151.016 over the 52-week period from its low, analysts note that the current valuation reflects both the legacy generic portfolio and the emerging innovative pipeline [3][5].

Analyst Outlook and Future Catalysts

Market analysts have adjusted their price targets following the regulatory news, with TD Cowen initiating coverage with a Buy rating and a price target of $55.00 on October 1, 2026 [2][8]. Oppenheimer raised its price target to $52 from $50, citing the Weltruza approval as a key driver for potential upside [6]. Consensus data indicates a Moderate Buy rating among Wall Street analysts, with a consensus price target of $44.67 [8]. Investors are now looking toward the next earnings report, scheduled for November 3, 2026, for further guidance on revenue integration from new approvals [2][5]. The company’s ability to execute the launch of Weltruza in the first half of 2027 will be a critical benchmark for long-term asset allocation in the biopharmaceutical sector [6].

Sources

Pharmaceuticals Stock Market